Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Allergy Therapeutics ( (GB:AGY) ) has provided an update.
Allergy Therapeutics has issued 13 new ordinary shares to finance the purchase and cancellation of 9,848,333 deferred shares, in line with shareholder-approved repurchase terms. This move has not affected the company’s ordinary shares in issue or the total voting rights, which remain at 4,766,439,951.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company specializing in allergy vaccines, focusing on developing treatments to address common allergies.
YTD Price Performance: 18.46%
Average Trading Volume: 523,094
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £367.1M
See more data about AGY stock on TipRanks’ Stock Analysis page.
